Nanobiotix SA
http://www.nanobiotix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nanobiotix SA
Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets
Following two record-breaking years for biotech fundraising, stock valuations are heading downwards. Biopharma executives and industry experts surveyed by Scrip anticipate big pharma executing more deals and acquisitions in 2022.
LianBio Gets Chinese Biotech US IPOs Rolling Again But Followers Scant
Billed as BridgeBio in China, US-based and China-oriented biotech LianBio breaks a long hiatus in US listing for Chinese biotechs.
Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- Curadigm